Get the Stockscreener App
283.80
1.60%
4.48
After Hours:
283.80
Natera Inc stock is traded at $283.80, with a volume of 1.35M.
It is up +1.60% in the last 24 hours and up +31.81% over the past month.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
See More
Previous Close:
$279.32
Open:
$277.5
24h Volume:
1.35M
Relative Volume:
0.88
Market Cap:
$40.64B
Revenue:
$2.50B
Net Income/Loss:
$-226.32M
P/E Ratio:
-172.92
EPS:
-1.6412
Net Cash Flow:
$71.51M
1W Performance:
+4.22%
1M Performance:
+31.81%
6M Performance:
+14.10%
1Y Performance:
+75.45%
1-Day Range:
$276.40
$288.04
1-Week Range:
$265.39
$288.04
52-Week Range:
$131.81
$288.04
Natera Inc Stock (NTRA) Company Profile
Name
Natera Inc
Sector
Industry
Phone
650-249-9090
Address
13011 MCCALLEN PASS, AUSTIN, CA
Compare NTRA vs TMO, DHR, IDXX, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NTRA
Natera Inc
|
283.80 | 38.88B | 2.50B | -226.32M | 71.51M | -1.6412 |
TMO
Thermo Fisher Scientific Inc
|
517.60 | 186.32B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
193.62 | 134.82B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
564.98 | 41.53B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
378.89 | 36.82B | 3.77B | 449.25M | 240.68M | 7.8556 |
Natera Inc Stock (NTRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-14-26 | Initiated | William Blair | Outperform |
| Jan-07-26 | Initiated | Citigroup | Buy |
| Dec-02-25 | Resumed | Morgan Stanley | Overweight |
| Oct-27-25 | Upgrade | BNP Paribas Exane | Underperform → Neutral |
| Sep-22-25 | Resumed | Wells Fargo | Equal Weight |
| Mar-13-25 | Initiated | RBC Capital Mkts | Outperform |
| Jan-23-25 | Initiated | Barclays | Overweight |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-08-24 | Resumed | Craig Hallum | Buy |
| Feb-20-24 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-29-23 | Reiterated | BTIG Research | Buy |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Nov-13-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-28-23 | Initiated | Bernstein | Mkt Perform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-05-23 | Initiated | UBS | Buy |
| Jan-18-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Apr-25-22 | Initiated | Stephens | Overweight |
| Mar-08-22 | Initiated | Goldman | Buy |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Jun-15-21 | Initiated | Raymond James | Mkt Perform |
| May-25-21 | Initiated | Wells Fargo | Overweight |
| Jan-28-21 | Initiated | Truist | Buy |
| Oct-08-20 | Initiated | BTIG Research | Buy |
| Sep-28-20 | Initiated | Morgan Stanley | Overweight |
| Sep-17-20 | Initiated | SVB Leerink | Outperform |
| Jun-10-20 | Resumed | Piper Sandler | Overweight |
| May-07-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-05-18 | Initiated | JP Morgan | Neutral |
| Jul-05-18 | Reiterated | Piper Jaffray | Overweight |
| Aug-07-17 | Reiterated | Morgan Stanley | Overweight |
| Nov-10-16 | Reiterated | The Benchmark Company | Buy |
| May-23-16 | Reiterated | The Benchmark Company | Buy |
| May-11-16 | Reiterated | The Benchmark Company | Buy |
| Apr-19-16 | Initiated | The Benchmark Company | Buy |
| Sep-28-15 | Upgrade | Wedbush | Neutral → Outperform |
| Aug-14-15 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-04-15 | Initiated | Robert W. Baird | Outperform |
| Jul-27-15 | Initiated | Morgan Stanley | Equal-Weight |
| Jul-27-15 | Initiated | Piper Jaffray | Overweight |
| Jul-27-15 | Initiated | Wedbush | Neutral |
View All
Natera Inc Stock (NTRA) Latest News
Why Natera (NTRA) Is Up 6.3% After New Signatera Cancer Trial And Japan Launch Milestones - simplywall.st
NTRA's Signatera secures PMDA approval for MRD testing in CRC in Japan - MSN
Form 144 NATERA For: 1 July By Investing.com - Investing.com Canada
Insider 10b5-1 sales reported for NTRA (NTRA) including 33,600 shares - Stock Titan
Director Solomon Moshkevich reports share sales (NTRA) - Stock Titan
What's Driving Natera's Recent Stock Action - Kavout | AI
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer - Yahoo Finance UK
Form 4 Natera Inc For: 30 June By Investing.com - Investing.com Australia
Natera (NTRA) director Monica Bertagnolli receives RSU grants for board service - Stock Titan
Natera (NASDAQ: NTRA) director receives RSU grants as board compensation - Stock Titan
Enterprise value to EBIT forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Enterprise value to revenue forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Natera Stock 5-Day Winning Spree: Stock Climbs 19% - Trefis
Natera Stock Surges 19%, With A 5-Day Winning Spree - Trefis
3 Stocks Estimated To Be Trading At A Discount Of Up To 48.9% - simplywall.st
Price to sales forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Natera, Aveta Biomics collaborate on head and neck cancer trial - Clinical Trials Arena
Price to earnings forward of Natera, Inc. – NASDAQ:NTRA - TradingView
NTRA & CytoDyn partner to advance ctDNA-guided development in mCRC - MSN
META_TITLE_QUOTE - Yahoo Finance
Natera, Aveta Biomics Ink Partnership to Support Phase III Trial in Head and Neck Cancer - Contract Pharma
Medical Services Name Tests For Colon Cancer. Natera Stock Hits A High. - Investor's Business Daily
NTRA Maintained by Guggenheim -- Price Target Raised to $290 - GuruFocus
Natera, Aveta partner on late-stage head and neck cancer trial - TradingView
Natera partners with Aveta for phase 3 head and neck cancer trial - Investing.com South Africa
Exploring 3 High Growth Tech Stocks in the US Market - simplywall.st
Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer - Lelezard
Natera partners with Aveta for phase 3 head and neck cancer trial By Investing.com - Investing.com India
Natera joins Aveta's global Phase 3 head and neck cancer trial - Stock Titan
Price to book forward of Natera, Inc. – NASDAQ:NTRA - TradingView
Supreme Court Declines to Hear CareDx Appeal in Natera False-Advertising CaseHealthcare Earnings Report - dars.gov.et
U.S. Supreme Court Rejects CareDxA’s Appeal in Natera, Inc. (NTRA) False-advertising Dispute - Insider Monkey
Natera climbs after Japanese nod for colorectal cancer test - MSN
Price-Driven Insight from (NTRA) for Rule-Based Strategy - Stock Traders Daily
Form 4 Natera Inc For: 26 June By Investing.com - Investing.com Nigeria
Natera director Herm Rosenman sells $4.13m in common stock - Investing.com UK
Natera(NTRA.US) Officer Sells US$8.46 Million in Common Stock - Moomoo
Insider Sell Alert: Herm Rosenman Sells 16,530 Shares of Natera Inc (NTRA) - GuruFocus
Natera director Herm Rosenman sells $4.13m in common stock By Investing.com - Investing.com Australia
Natera Inc (NTRA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Natera legal officer Daniel Rabinowitz sells $8.45m in shares - Investing.com
Natera legal officer Daniel Rabinowitz sells $8.45m in shares By Investing.com - Investing.com South Africa
Natera (NTRA) director’s 10b5-1 sale leaves 4,250 shares - Stock Titan
Natera (NTRA) chief legal officer sells 33,600 shares in pre-set 10b5-1 trades - Stock Titan
Natera(NTRA.US) Director Sells US$4.13 Million in Common Stock - Moomoo
Bernstein resumes Natera stock coverage with outperform rating By Investing.com - Investing.com Australia
Natera (NTRA) Partners With Eledon To Put Prospera Into Phase 3 Kidney Trial - simplywall.st
Natera (NTRA) Receives Outperform Rating and $310 Target from Be - GuruFocus
Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise - Seeking Alpha
Bernstein resumes Natera stock coverage with outperform rating - Investing.com UK
NTRA Reiterated by Bernstein -- Price Target Announced at $310 - GuruFocus
Natera Inc Stock (NTRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
1.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):